NCT04498481View on ClinicalTrials.gov

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

CompletedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

July 1, 2018

Study Completion Date

July 1, 2018

Conditions
Breast Cancer
Trial Locations (1)

10017

Pfizer United States, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY